导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.85% | 2686/4772 |
| 近一周 | -0.70% | 1632/5490 |
| 近一月 | -3.09% | 2100/5407 |
| 近一季 | -3.09% | 2406/5201 |
| 近半年 | -3.78% | 2249/4918 |
| 近一年 | 0.39% | 2691/4355 |
| 近两年 | 43.31% | 1757/2950 |
| 近三年 | 22.52% | 1350/2241 |
| 成立以来 | 71.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.88% 2940/4961 |
11.70% 2304/5312 |
- - |
- - |
| 2025 | 18.87% 2274/4813 |
-0.92% 2465/3635 |
1.73% 2194/4076 |
18.18% 2338/4524 |
-0.21% 2417/4813 |
| 2024 | 13.08% 1181/3463 |
1.94% 839/2808 |
-1.78% 1106/3014 |
16.06% 1549/3129 |
-2.70% 2163/3463 |
| 2023 | -11.23% 1380/2656 |
3.45% 1195/2280 |
-5.05% 1360/2385 |
-3.59% 957/2515 |
-6.25% 1691/2655 |
| 2022 | -20.45% 971/2207 |
-14.54% 965/1919 |
6.93% 573/2016 |
-13.09% 831/2113 |
0.16% 1532/2208 |
| 2021 | 1.06% 694/1822 |
-2.68% 689/1255 |
7.88% 661/1330 |
-5.53% 818/1466 |
1.88% 764/1822 |
| 2020 | 35.26% 421/1250 |
-6.22% 471/1028 |
15.38% 506/1067 |
10.52% 542/1164 |
13.10% 395/1184 |
| 2019 | 30.98% 478/1092 |
25.06% 483/739 |
-3.71% 401/788 |
4.70% 186/850 |
3.89% 824/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 前海开源MSCI中国A股指数C VS. 长安沪深300非周期A(740101) |